Sarepta Therapeutics, Inc. Discusses Q3 2013 Results (Webcast)

Nov.12.13 | About: Sarepta Therapeutics, (SRPT)

Sarepta Therapeutics (SRPT): Q3 EPS of -$0.63 in-line. Revenue of $4.2M misses by $0.37M. (PR)

The following audio is from a conference call that will begin on November 12, 2013 at 08:00 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion.

If you would like to view a transcript of this call, please click here.